-
Product Insights
NewLymphoproliferative Disorders – Drugs In Development, 2024
Empower your strategies with our Lymphoproliferative Disorders – Drugs In Development, 2024 report and make more profitable business decisions. Lymphoproliferative disorders (LPD) constitute a diverse group of diseases marked by uncontrolled lymphocyte production, resulting in monoclonal lymphocytosis, lymphadenopathy, and bone marrow infiltration. Predominantly affecting immunocompromised individuals, these disorders involve two subsets of lymphocytes, T and B cells, leading to immunoproliferative disorders with inherent risks of immunodeficiency and lymphocyte dysregulation. Causative gene mutations, whether iatrogenic or acquired, are identified through somatic or...
-
Product Insights
NewPost-Transplant Lymphoproliferative Disorder – Drugs In Development, 2024
Empower your strategies with our Post-Transplant Lymphoproliferative Disorder – Drugs In Development, 2024 report and make more profitable business decisions. Post-Transplant Lymphoproliferative Disorder is a complication of organ transplantation and is a life-threatening condition. Infections occurring because of low immunity like EBV (Epstein-Barr virus) also known common cause. Symptoms are non-specific and varies from one another but most commonly fever, malaise, weight loss are seen. EBV tests, CBP, Urine analysis, CT-scan, PET scan are the common diagnostics methods. As Immunosuppressants are...